top of page
ABOUT LUTETIA

Building a global biotech for multimodal neurology.

Lutetia Therapeutics was created in 2026 around a clinically advanced CMT1A program and a clear ambition: advance LUT001 while building the next generation of multimodal therapies in CMT1A, ALS and Alzheimer’s disease.

Established in 2026 · Incorporated in Delaware, United States

OUR STARTING POINT

A new company. A tangible starting point.

Lutetia was established in 2026 with something unusual for a new biotechnology company: a clinically advanced starting program and years of accumulated development data.

The 2026 acquisition of Pharnext-origin patents and clinical and regulatory data provides the foundation for LUT001, Lutetia’s lead program in CMT1A.

That foundation allows Lutetia to focus immediately on the questions that matter for the program’s next stage: clinical evidence, CMC and manufacturing, regulatory strategy and execution.

2026

Lutetia Therapeutics established

2026

Pharnext-origin patents and data acquired

Today

LUT001 development strategy and next-generation neurology programs

LEADERSHIP

Leadership for the next stage.

Lutetia brings together leadership across company building, clinical development, data and international biopharma execution.

Board

Jean-Jacques Bienaimé

Executive Chairman

Jean‑Jacques Bienaimé, MBA, is Executive Chairman of Lutetia Therapeutics, overseeing corporate strategy, financing, governance, and commercialization planning. He brings more than three decades of biopharmaceutical leadership, with deep expertise in rare‑disease development and global product launches. For 18 years, he served as Chairman and CEO of BioMarin Pharmaceutical, helping build it into a leading rare‑disease company. Over his career, he contributed to the development and commercialization of eight pediatric rare‑disease therapies. He also serves on multiple biotechnology boards and advises emerging companies on strategic growth and long‑term value creation.

Darith Phat

Founder & Chief Executive Officer

Darith Phat, PhD, MS, MBA, is the Founder and CEO of Lutetia Therapeutics, leading the intellectual‑property acquisition and regulatory rescue of LUT001 (PXT3003) for Charcot‑Marie‑Tooth disease type 1A. A biopharma leader with over a decade of experience in translational research, asset acquisition, and cross‑border partnering, Dr. Phat has advised senior biotech executives and held academic appointments at Georgetown University and École Centrale Paris, mentoring students who later became CEOs of major pharmaceutical companies. He earned his PhD from CentraleSupélec, an MS from UC San Diego, and an MBA from IMD Lausanne, and serves on the board of CamEd Business School.

Executive leadership

Key Operations / Functional Leads

Jamunabai Prakash, MS (Jem):

VDR & IP Management / Alliance Management / Operations

Studio photography of a man in a dark suit and white shirt, smiling confidently. He has a professional and friendly demeanor in this headshot.

Yannis Jemiai

Fractional Chief Data Science Officer

Yannis Jemiai, PhD, is Co-Founder and Chief Data Science Officer at Lutetia Therapeutics, leading statistical strategy for its neuroscience pipeline. With over 20 years of experience in biostatistics and clinical development, he applies adaptive and Bayesian trial design, causal inference, real-world evidence and AI/ML. Former Chief Scientific Officer at Cytel, he guided its consulting and software divisions through two private-equity transactions. He holds a Harvard PhD in Biostatistics and advises multiple life-science companies.

Digital portrait of a woman with shoulder-length brown hair and a warm smile. She has a friendly and professional demeanor against a dark background.

Priya Jambhekar

Chief Regulatory and Quality Officer & Scientific Advisory Board Member

Priya Jambhekar is Chief Regulatory & Quality Officer at Lutetia Therapeutics, leading LUT001’s global regulatory strategy, health authority interactions and quality systems. With over 30 years of experience, she is President and CEO of PBS Regulatory Consulting Group. Previously, she served as Global SVP of Regulatory & Quality at Paramount BioSciences and Global VP at Ethicon (Johnson & Johnson) and Alkermes. She has guided numerous global NDA, MAA and IND filings for small molecules, biologics and cell therapies through the FDA, EMA and other health authorities.

Studio portrait of a man wearing glasses and a grey blazer, smiling warmly. He exudes professional confidence.

Praveen Kandi

Vice President, Head of CMC

Praveen Kandi, PhD, is CMC Head at Lutetia Therapeutics, bringing over 22 years of experience in CMC strategy, drug development, technology transfer and commercialization. His career spans Amani Therapeutics, RTW Investments, Transneural Therapeutics, Bristol Myers Squibb–Karuna Therapeutics and Thermo Fisher Scientific. A key CMC leader for COBENFY® (KarXT), he contributed to its FDA approval. He combines scientific expertise, operational excellence and strategic partnership leadership to accelerate development, optimize capital efficiency and advance innovative medicines toward global commercialization.

Carlos Gonzalez

Fractional Chief Financial Officer

Carlos Gonzalez is CFO at Lutetia Therapeutics, overseeing financial planning, reporting and Series A diligence readiness. He brings over 30 years of experience, including 20+ fractional CFO engagements with VC-backed startups from Seed to Series A, notably in biotech. Previously, he served as CFO of a €1.8 billion investment fund. An IESE Executive MBA graduate, he has worked across the US, Europe and Singapore and is active in the San Francisco Bay Area startup ecosystem, with a particular interest in AI and finance.

Carlos-headshot.png

SCIENTIFIC & STRATEGIC ADVISORS

Scientific & Strategic Advisory Boards

I — Lutetia Scientific Advisory Board (SAB), Opinion Leaders (KOLs)

CMT & Neurology Clinical Experts

Additional Scientific & Regulatory Expertise

II — Strategic Advisory Board & Commercial Leaders

Commercial & Valuation Strategy

Lauren Cohen, PhD

Member, Commercial & Valuation Strategy (L.E. Simmons Chaired Professor, Harvard Business School).

Dr. David Herrmann

Professor of Neurology & Neuromuscular Division Chief (University of Rochester); leading collaboration on ACT-CMT natural history datasets and longitudinal ONLS/CMTNS endpoint controls.

Dr. Florian Thomas

Chair of Neurology & Director, CMT Center of Excellence (Hackensack Meridian); advising on neuromuscular clinical trials, natural history trajectories, and patient registry integration.

Dr. Michael Sereda

Professor of Neurology & Head of Neurogenetics (University Medical Center Göttingen / Max Planck Institute); engaged regarding German NHS dataset analysis, meta-analysis steering committee, and CMT endpoint evaluation.

Clinical & Regulatory Strategy

Jonathon Parker, PhD

Lead Regulatory Advisor (SAB); packaging FDA regulatory narrative, aligning US/China trial data, and guiding Pre-NDA strategy.

Biostatistics & Regulatory Strategy

Philippe Lehert, PhD

Lead Biostatistician (SAB); former UN Senior Consulting Statistician directing meta-analyses, pooled trial re-evaluations, and statistical strategies.

Regulatory & CMC Strategy

Ramesh Sood, PhD

Member, Scientific Advisory Board (Former FDA CMC Branch Chief & Regulatory Strategy Advisor).

Formulation & Drug Delivery

Rodney JY Ho, PhD

Member, CMC Advisory Board (Professor of Pharmaceutics, University of Washington); specialist in combination drug solutions, formulation stability, and delivery platforms.

PURPOSE

A clear purpose. A bold but focused ambition.

MISSION

Advance therapies with the potential to make a meaningful difference for people living with serious neurological diseases.

VISION

Address biological complexity through rigorous multimodal therapeutic strategies.

AMBITION

Build a globally relevant neurology biotech anchored by LUT001 and expanded through next-generation CMT1A, ALS and Alzheimer’s disease programs.

HOW WE BUILD

Advance. Create. Execute.

Scientific potential creates opportunity. Development discipline turns that opportunity into progress.

Advance

Move LUT001 toward the most rigorous feasible global development path.

Create

Build next-generation multimodal programs with scientific discovery collaborators.

Execute

Bring together the clinical, regulatory, data, CMC, manufacturing and partnering capabilities needed to move selected programs forward.

Different programs require different capabilities. Lutetia’s model is designed to assemble the expertise each stage demands.

GLOBAL BY DESIGN

Global from the start.

Lutetia is building its development strategy across the United States and Europe, with Japan under evaluation. The company’s scientific and development network is intentionally international.

For LUT001, clinical evidence, manufacturing requirements and regulatory feedback will determine the path forward. Future programs will be built with the same global development mindset.

United States

Development and regulatory strategy

Europe

Clinical and regulatory planning

Japan

Opportunity under evaluation

The separate PXT3003 program in China is led by Tasly/GeneNet.

WHAT COMES NEXT

Building the next generation of multimodal therapies in neurology.

Lutetia is combining a clinically advanced starting program with a focused research pipeline and a global development mindset.

We welcome conversations with investors, biopharma partners and scientific collaborators who want to help turn that potential into progress.

bottom of page